Why choose CUBEBIO
The start of early cancer detection
So that anyone can screen for cancer simply and non-invasively, CUBEBIO designs every moment of diagnosis — from the urine specimen to the result.
Urine specimen
Non-invasive screening with a urine sample — no blood draw, no discomfort.
Patented technology
Metabolite-based early detection technology protected by domestic and international patents.
Accessible screening
Expanding cancer screening beyond medical institutions to everyday life.
Diagnostics across four product lines
From colorimetric reagents to cuvettes, biosensors and diagnostic equipment.
CEED-Novus Series
Colorimetric reagents for urine-based metabolite analysis. Color change in the reagent reveals metabolite concentration at a glance.
CEED-SP / CEED-SPC
Cuvette products for spectrophotometric measurement. Precise optical analysis quantifies metabolite concentration.
CEED-PG / CEED-PGS
Biosensors that detect cancer metabolites electrochemically — fast, precise results from a small specimen.
CEED-SA · CMDD Series · CSDD
Diagnostic equipment and accessories for screening, in a range of formats to suit any testing site.
2025-08-25
[2025.08.25] CUBEBIO Co., Ltd. enters MENA·EU in earnest, signed distribution and investment agreement
Read more
2025-06-23
[2025.06.23] CUBEBIO Co., Ltd. Collaborates with Korean Medical Institutions and Global Reinsurer on Pancreatic Cancer Screening Service Through Four-Party Agreement
Read more
2025-04-15
[2025.04.14] CUBEBIO Co., Ltd. Secures 4.6 Trillion KRW Export Deal with India for Urine-Based Cancer Screening Products
Read more
Interested in partnership or distribution?
Talk to CUBEBIO about early cancer screening solutions.